Negative p53/Positive p21 Immunostaining Is a Predictor of Favorable Response to Chemotherapy in Patients with Locally Advanced Bladder Cancer.

KOGA F; KITAHARA S; ARAI K; HONDA M; SUMI S; YOSHIDA K

Art

J-GLOBAL ID：200902165381682804 Reference number：00A0428881

Negative p53/Positive p21 Immunostaining Is a Predictor of Favorable Response to Chemotherapy in Patients with Locally Advanced Bladder Cancer.

p53陰性およびp21陽性免疫染色は局所性進行性ぼうこう癌患者における化学療法に対する良好な応答の指標である

Publisher site Copy service {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=00A0428881&COPY=1") }}
Access JDreamⅢ for advanced search and analysis. {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=00A0428881&from=J-GLOBAL&jstjournalNo=F0633A") }}

Author (6)： , , , , ,
Material：
Volume： 91 Issue： 4 Page： 416-423 Publication year： Apr. 30, 2000
JST Material Number： F0633A ISSN： 0910-5050 Document type： Article
Article type：原著論文 Country of issue： Japan (JPN) Language： ENGLISH (EN)

,...
,...

To see more with JDream III (charged). {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=00A0428881&from=J-GLOBAL&jstjournalNo=F0633A") }}

Diagnosis of tumors(=neoplasms) , Urogenital tumors(=neoplasms)

Reference (30)：

MCCAFFREY, J. A. Combined-modality therapy for bladder cancer. Oncology (Huntingt.). 1997, 11, 18-26
FREIHA, F. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J. Urol. 1996, 155, 495-500
SPLINTER, T. A. W. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. J. Urol. 1992, 147, 606-608
STERNBERG, C. N. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder. Cancer. 1993, 72, 1975-1982
ARIMA, K. Balloon-occluded arterial infusion as a useful neoadjuvant chemotherapy for bladder cancer. Br. J. Urol. 1997, 80, 417-420

ｍore...

, , , , , , , ,

Return to Previous Page